Lv1
10 积分 2024-05-15 加入
Xalnesiran with or without an immunomodulator in chronic hepatitis B
1天前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
1天前
求助中
The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075
7天前
已完结
Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand
7天前
已完结
Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference
8天前
已完结
Design, synthesis, and biological evaluation of indole-2-carboxamides as SARS CoV-2 main protease inhibitors
10天前
已完结
Design, synthesis, and biological evaluation of indole-2-carboxamides as SARS CoV-2 main protease inhibitors
11天前
已完结
STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression
3个月前
已完结
Construction of expression vector of siRNA specific for STAT5a and identification of its efficiency in MGC803 gastric cancer cell line
3个月前
已完结
The role of apolipoprotein A5 in non-alcoholic fatty liver disease
5个月前
已完结
皖公网安备34019202002308
